Eris Lifesciences Acquires Velbiom’s Probiotics Business For ₹500 Million

Eris Lifesciences Ltd, a leading player in India’s pharmaceutical industry, has finalized the purchase of Velbiom Probiotics’ business. The acquisition underscores Eris’s focus on tapping into emerging healthcare segments and enhancing its competitive edge in specialty therapies.  

Strategic Significance  
The probiotics market in India has been witnessing strong growth, driven by rising awareness of gut health and preventive care. By acquiring Velbiom’s portfolio, Eris gains access to established brands and distribution channels, positioning itself to capture greater market share.  

Financial Consideration  
The acquisition was completed for ₹500 million on a slump sale basis, ensuring a seamless transfer of assets and operations. This structure allows Eris to integrate the business efficiently while minimizing complexities.  

Recent Developments  

• Eris Lifesciences acquires Velbiom Probiotics business  
• Deal valued at ₹500 million on slump sale basis  
• Strengthens presence in probiotics and preventive healthcare  
• Expands product portfolio and distribution reach  

Future Outlook  
Analysts expect the acquisition to accelerate Eris’s growth in niche therapeutic areas. With probiotics gaining traction among consumers and healthcare professionals, the company is well-positioned to leverage this trend and drive long-term value creation.  

Sources: Economic Times, Business Standard, Mint, Reuters